Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Donepezil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 8/20 | 1.00 |
| ▸ | BCHE | P06276 | 8/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Donepezil SCHEMBL3516 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL8265876 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL2149 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL3851203 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL3967195 | 0.99 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL1815 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL4979379 | 0.99 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL356844 | 0.99 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL5060933 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL1559622 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025073915-A1 | TREATMENT OF LEUKODYSTROPHY | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy (IE) | 2025-04-10 | — | — | WO | claimed |
| WO-2025229537-A1 | PHARMACEUTICAL COMBINATION OF DONEPEZIL AND CEVIMELINE | LUKA ASSETS INC. (US) | 2025-11-06 | — | — | WO | disclosed |
| WO-2022093722-A1 | A LIQUID INJECTABLE COMPOSITION OF DONEPEZIL | PTS CONSULTING, LLC (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7563808-B2 | Methods for treating cognitive impairments or dementia | EISAI CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20090131480-A1 | Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia | EISAI CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090042939-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042940-A1 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080167343-A1 | Methods and compositions using cholinesterase inhibitors | EISAI CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20070129402-A1 | Donepezil; pharmacokinetics; single-dose administration of the formulation to a patient provides a blood plasma level profile with a dosage-corrected Cmax | EISAI RESEARCH INSTITUTE (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ACHE 18/4885BCHE 42/4885FAAH 1060/4885 |
| US-20080167343-A1 | Methods and compositions using cholinesterase inhibitors | PSEN1, BACE1, PSENEN | ACHE 26/4885BCHE 137/4885FAAH 861/4885 |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | ACHE, CHRNA5, CHRNA2 | ACHE 1/4885BCHE 35/4885FAAH 422/4885 |
| US-20090131480-A1 | Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia | CHRNA5, GRIN1, GRIK5 | ACHE 33/4885BCHE 48/4885FAAH 1268/4885 |
| US-20070129402-A1 | Donepezil; pharmacokinetics; single-dose administration of the formulation to a patient provides a blood plasma level profile with a dosage-corrected Cmax | CYP3A5, SLC6A2, SLC6A4 | ACHE 4/4885BCHE 10/4885FAAH 953/4885 |
| US-20090042939-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | ACHE 26/4885BCHE 137/4885FAAH 861/4885 |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | NOTCH3, NOTCH2, NOTCH4 | ACHE 156/4885BCHE 38/4885FAAH 1617/4885 |
| US-20090042940-A1 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | PSEN1, BACE1, PSENEN | ACHE 26/4885BCHE 137/4885FAAH 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.